[18F] - FD17 PET Imaging of α-synuclein: A Clinical Study in α-synucleinopathy Patients

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This trial used a new radioactive tracer called [18F]-FD17 to image alpha-synuclein in the brain — since it's already completed, has any safety or findings data been published that you could help me understand, and what might it mean for my diagnosis?
2. 2The primary outcomes here were safety checks like ECGs, blood tests, urine tests, and liver and kidney function — does that tell us anything about what the researchers were most cautious about with this tracer, and should those same markers be something I monitor in my own care?
3. 3Since this study enrolled people with conditions like Parkinson's disease, Multiple System Atrophy, and REM sleep behavior disorder, do you think my specific diagnosis would have been relevant to a study like this, and are there similar alpha-synuclein imaging studies still recruiting that I might be eligible to discuss?
4. 4Alpha-synuclein imaging is still an emerging area — based on what you know about where this research stands, how close are we to having this kind of PET scan available as a real diagnostic tool, and could that timing affect how my condition is monitored going forward?
5. 5Are there other completed or ongoing studies using PET imaging for alpha-synuclein that you'd recommend I look into, or is standard diagnostic imaging still the more reliable path for someone in my situation right now?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.